The multi-branch Algol is developed with continuity and long-term ownership in mind

In a multi-branch Algol Group, we build success and responsible future for our partners. Having companies in several different branches of industry enables a controlled level of risk while creating versatile growth opportunities. The Algol Group strategy is based on the operational independence of the business areas combined with the Group's financial support and focused ownership steering.

Growth and profit in an unstable market situation

The development of the Algol Group's business remained stable in 2025, with a revenue of 198 million euros.

	2025	2024	2023
Net sales, M€	198	194	208
EBITDA, M€	8.8	9.3	13.7
EBIT, M€	6.9	7.8	12.2
Results after taxes, M€	4.8	5.9	8.5
ROE, %	12.4	16	26
Solidity, %	51.3	49.6	44.7
Net debt, M€	Net debt free	Net debt free	Net debt free
Number of personnel on av.	486	485	465

Algol Group Financial Statement Summary 2025

News: Growth and profit in an unstable market situation

Algol

Algol is a Finnish family-owned business and a multi-branch company, which has been active in international trade since 1894. The Group comprises Algol Chemicals, Algol Diagnostics, Algol Technics, Algol Trehab, Histolab Products and Suomen Unipol.

The basis of our operations

Trading involves responsibility for customers, suppliers, employees and society as a whole. We believe that international trade promotes global understanding, peaceful coexistence and stability.

Corporate governance

The Group comprises six business units: Algol Chemicals, Algol Diagnostics, Algol Technics, Algol Trehab, Histolab Products and Suomen Unipol.

Financial information

History

Algol was established in Helsinki in January 1894 as an agency business supplying Finnish industry with metals, industrial chemicals and building materials.